PTCT

PTC Therapeutics, Inc.

35.63 USD
+0.01 (+0.03%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

PTC Therapeutics, Inc. stock is down -11.19% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 54.55% of the previous 11 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 5 PUTs, 5 CALLs. 25% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
25 Apr 15:36 21 Jun, 2024 25.00 PUT 1529 310
25 Apr 15:36 21 Jun, 2024 25.00 PUT 326 310
25 Apr 16:57 21 Jun, 2024 26.00 CALL 160 51
10 May 14:10 21 Jun, 2024 26.00 CALL 51 253
14 May 14:30 21 Jun, 2024 33.00 CALL 200 201
20 May 15:31 21 Mar, 2025 25.00 CALL 15 15
10 Jun 19:49 19 Jul, 2024 37.00 PUT 292 0
11 Jun 14:53 21 Jun, 2024 27.00 CALL 175 175
12 Jun 13:38 19 Jul, 2024 37.00 PUT 148 578
12 Jun 13:45 19 Jul, 2024 37.00 PUT 148 578

About PTC Therapeutics, Inc.

PTC Therapeutics focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; Tegsedi and Waylivra for the. treatment of rare diseases in Latin America and the Caribbean. PTC518 is being developed for Huntington's disease.

  • Goldman Sachs
    Tue May 28, 11:45
    sell
    confirm
  • Citigroup
    Tue May 21, 13:59
    sell
    confirm
  • JP Morgan
    Tue May 21, 12:05
    buy
    confirm
  • Goldman Sachs
    Tue May 21, 10:14
    sell
    confirm